
    
      This is a Phase I, open-label, non-randomised, multicenter single-dose study to evaluate PK,
      PD, and safety of a single oral dose of MT-1303 in subjects with moderate to severe active
      Crohn's disease (ileal and ileo-colonic type).
    
  